Bristol Myers Squibb to Build $2.3 Billion Multi-Modal Manufacturing Campus in Houston

Bristol Myers Squibb has selected Generation Park in Houston, Texas, as the site for a new, approximately $2.3 billion manufacturing campus designed to support production of next-generation medicines.¹ The roughly 600,000-square-foot facility will create nearly 500 skilled jobs and is designed with modular architecture that allows capacity to be added or reconfigured as the company's pipeline evolves.¹ The investment is part of BMS's broader $40 billion commitment to US-based research and development, technology, and domestic manufacturing over five years.¹

What makes this campus "multi-modal"?

Unlike a facility built around a single production platform, the Houston campus is designed from the outset to manufacture multiple types of medicines, including small molecules, biologics, and antibody-drug conjugates, across a range of disease areas, supporting drug product and finished goods manufacturing from late development through launch.¹ Karin Shanahan, executive vice president and chief supply chain and operations officer of Bristol Myers Squibb, said, "Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region's ability to support a world-class, digitally advanced supply operation. This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands."¹

How does this fit into the broader domestic manufacturing investment trend?

BMS's announcement follows a wave of large-scale US manufacturing investments from other major biopharmaceutical companies at the same Houston development. Eli Lilly and Company announced plans in September 2025 to build a $6.5 billion active pharmaceutical ingredient facility at the same Generation Park site, focused on small molecule medicines including its oral GLP-1 candidate orforglipron. Texas extended a $4.89 million Texas Enterprise Fund grant to support the BMS project, following a competitive evaluation of multiple markets across the Central and Eastern US.¹ The US biopharmaceutical industry directly employed more than one million workers in 2022 and, with an employment multiplier of 4.69, supported more than 4.9 million total jobs across the broader economy, according to industry data cited in the release.²

What did company and government leadership say?

Christopher Boerner, PhD, board chair and chief executive officer of Bristol Myers Squibb, said, "This investment reflects our confidence in America's continued leadership in biopharmaceutical innovation. As part of our $40 billion commitment to the United States, we're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life."¹ Texas Governor Greg Abbott added, "Texas is a global hub for life sciences, where today's innovations shape the future of healthcare. This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities."¹

What happens next?

BMS expects the Houston campus to create approximately 2,000 construction and other indirect jobs between 2027 and 2030 as the facility is built and brought online.¹ The nearly 500 initial permanent roles will span operations technicians, production specialists, maintenance and engineering professionals, quality control and assurance experts, and site leadership.¹ BMS invested approximately $10 billion in research and development in 2025 and currently works with a contract manufacturer in Texas for commercial and clinical trial manufacturing, having operated 250 clinical trial sites throughout the state in 2025.¹

References

1. Bristol Myers Squibb advances U.S. manufacturing investment with new $2.3 billion campus in Houston, Texas. News release. Bristol Myers Squibb; August 10, 2026. Accessed August 10, 2026.
2. TEConomy Partners, LLC. The economic impact of the U.S. biopharmaceutical industry. Pharmaceutical Research and Manufacturers of America (PhRMA); 2024. Accessed August 10, 2026.